The cerebrospinal fluid CD4/CD8 ratio and interleukin-6 and -10 levels in neurosarcoidosis: a multicenter, pragmatic, comparative study.
Adult
Biomarkers
/ cerebrospinal fluid
CD4-CD8 Ratio
Central Nervous System Diseases
/ cerebrospinal fluid
Cerebrospinal Fluid
/ cytology
Female
Humans
Inflammation
/ cerebrospinal fluid
Interleukin-10
/ cerebrospinal fluid
Interleukin-6
/ cerebrospinal fluid
Male
Middle Aged
Multiple Sclerosis
/ cerebrospinal fluid
Progression-Free Survival
Recurrence
Retrospective Studies
Sarcoidosis
/ cerebrospinal fluid
Treatment Outcome
Young Adult
central nervous system
cerebrospinal fluid
cytokine
interleukin
sarcoidosis
tocilizumab
Journal
European journal of neurology
ISSN: 1468-1331
Titre abrégé: Eur J Neurol
Pays: England
ID NLM: 9506311
Informations de publication
Date de publication:
10 2019
10 2019
Historique:
received:
16
12
2018
accepted:
23
04
2019
pubmed:
26
4
2019
medline:
12
8
2020
entrez:
26
4
2019
Statut:
ppublish
Résumé
Neurosarcoidosis is a rare inflammatory disorder of unknown cause. The aim of this study was to evaluate the value of T/B lymphocyte population counts and the concentrations of the cytokines interleukin (IL) 6 and IL-10 in the cerebrospinal fluid (CSF) of neurosarcoidosis patients. A retrospective study CSF biomarkers was conducted in patients with neurosarcoidosis who underwent CSF analysis between 2012 and 2017 as well as various control populations. Forty-three patients with neurosarcoidosis, 14 with multiple sclerosis (MS) and 48 with other inflammatory disorders were analyzed. The CSF IL-6 levels were higher in sarcoidosis patients than in MS patients (median 8 vs. 3 pg/ml, P = 0.006). The CSF CD4/CD8 ratio was higher in sarcoidosis patients than in MS patients and in patients with other inflammatory disorders (median 3.18 vs. 2.36 and 2.10, respectively, P = 0.008). The CSF IL-6 level was higher in patients with active neurosarcoidosis than in non-active neurosarcoidosis patients (median 13 vs. 3 pg/ml, P = 0.0005). In patients with neurosarcoidosis, a CSF IL-6 concentration >50 pg/ml was associated with a higher risk of relapse or progression-free survival (hazard ratio 3.60; 95% confidence interval 1.78-23.14). A refractory neurosarcoidosis patient was treated with an anti-IL-6 monoclonal antibody that produced a complete neurological response. The CSF CD4/CD8 ratio and IL-6 concentration are increased in neurosarcoidosis compared to MS and other inflammatory disorders. A CSF IL-6 concentration >50 pg/ml is associated with relapse or progression of neurosarcoidosis. IL-10 levels may be elevated in neurosarcoidosis.
Sections du résumé
BACKGROUND AND PURPOSE
Neurosarcoidosis is a rare inflammatory disorder of unknown cause. The aim of this study was to evaluate the value of T/B lymphocyte population counts and the concentrations of the cytokines interleukin (IL) 6 and IL-10 in the cerebrospinal fluid (CSF) of neurosarcoidosis patients.
METHODS
A retrospective study CSF biomarkers was conducted in patients with neurosarcoidosis who underwent CSF analysis between 2012 and 2017 as well as various control populations.
RESULTS
Forty-three patients with neurosarcoidosis, 14 with multiple sclerosis (MS) and 48 with other inflammatory disorders were analyzed. The CSF IL-6 levels were higher in sarcoidosis patients than in MS patients (median 8 vs. 3 pg/ml, P = 0.006). The CSF CD4/CD8 ratio was higher in sarcoidosis patients than in MS patients and in patients with other inflammatory disorders (median 3.18 vs. 2.36 and 2.10, respectively, P = 0.008). The CSF IL-6 level was higher in patients with active neurosarcoidosis than in non-active neurosarcoidosis patients (median 13 vs. 3 pg/ml, P = 0.0005). In patients with neurosarcoidosis, a CSF IL-6 concentration >50 pg/ml was associated with a higher risk of relapse or progression-free survival (hazard ratio 3.60; 95% confidence interval 1.78-23.14). A refractory neurosarcoidosis patient was treated with an anti-IL-6 monoclonal antibody that produced a complete neurological response.
CONCLUSIONS
The CSF CD4/CD8 ratio and IL-6 concentration are increased in neurosarcoidosis compared to MS and other inflammatory disorders. A CSF IL-6 concentration >50 pg/ml is associated with relapse or progression of neurosarcoidosis. IL-10 levels may be elevated in neurosarcoidosis.
Substances chimiques
Biomarkers
0
IL10 protein, human
0
IL6 protein, human
0
Interleukin-6
0
Interleukin-10
130068-27-8
Types de publication
Comparative Study
Journal Article
Multicenter Study
Pragmatic Clinical Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
1274-1280Informations de copyright
© 2019 EAN.
Références
Valeyre D, Prasse A, Nunes H, Uzunhan Y, Brillet PY, Muller-Quernheim J. Sarcoidosis. Lancet 2014; 383: 1155-1167.
Cohen Aubart F, Galanaud D, Haroche J, et al. Neurosarcoidosis: diagnosis and therapeutic issues. Rev Med Interne 2017; 38: 393-401.
Hoitsma E, Faber CG, Drent M, Sharma OP. Neurosarcoidosis: a clinical dilemma. Lancet Neurol 2004; 3: 397-407.
Zajicek JP, Scolding NJ, Foster O, et al. Central nervous system sarcoidosis - diagnosis and management. QJM 1999; 92: 103-117.
Bitoun S, Bouvry D, Borie R, et al. Treatment of neurosarcoidosis: a comparative study of methotrexate and mycophenolate mofetil. Neurology 2016; 87: 2517-2521.
Wengert O, Rothenfusser-Korber E, Vollrath B, et al. Neurosarcoidosis: correlation of cerebrospinal fluid findings with diffuse leptomeningeal gadolinium enhancement on MRI and clinical disease activity. J Neurol Sci 2013; 335: 124-130.
Welker L, Jorres RA, Costabel U, Magnussen H. Predictive value of BAL cell differentials in the diagnosis of interstitial lung diseases. Eur Respir J 2004; 24: 1000-1006.
Stern BJ, Griffin DE, Luke RA, Krumholz A, Johns CJ. Neurosarcoidosis: cerebrospinal fluid lymphocyte subpopulations. Neurology 1987; 37: 878-881.
Wang L, Luo L, Gao Z, et al. The diagnostic and prognostic value of interleukin-10 in cerebrospinal fluid for central nervous system lymphoma: a meta-analysis. Leuk Lymphoma 2017; 58: 2452-2459.
Nguyen-Them L, Costopoulos M, Tanguy ML, et al. The CSF IL-10 concentration is an effective diagnostic marker in immunocompetent primary CNS lymphoma and a potential prognostic biomarker in treatment-responsive patients. Eur J Cancer 2016; 61: 69-76.
Ikeguchi R, Shimizu Y, Shimizu S, Kitagawa K. CSF and clinical data are useful in differentiating CNS inflammatory demyelinating disease from CNS lymphoma. Mult Scler 2018; 24: 1212-1223.
Saruhan-Direskeneli G, Yentur SP, Akman-Demir G, Isik N, Serdaroglu P. Cytokines and chemokines in neuro-Behcet's disease compared to multiple sclerosis and other neurological diseases. J Neuroimmunol 2003; 145: 127-134.
Akman-Demir G, Tuzun E, Icoz S, et al. Interleukin-6 in neuro-Behcet's disease: association with disease subsets and long-term outcome. Cytokine 2008; 44: 373-376.
Sasagawa Y, Akai T, Tachibana O, Iizuka H. Diagnostic value of interleukin-10 in cerebrospinal fluid for diffuse large B-cell lymphoma of the central nervous system. J Neurooncol 2015; 121: 177-183.
Sasayama T, Nakamizo S, Nishihara M, et al. Cerebrospinal fluid interleukin-10 is a potentially useful biomarker in immunocompetent primary central nervous system lymphoma (PCNSL). Neuro Oncol 2012; 14: 368-380.
Emile JF, Abla O, Fraitag S, et al. Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages. Blood 2016; 127: 2672-2681.
Bridel C, Courvoisier DS, Vuilleumier N, Lalive PH. Cerebrospinal fluid angiotensin-converting enzyme for diagnosis of neurosarcoidosis. J Neuroimmunol 2015; 285: 1-3.
Shen Y, Pang C, Wu Y, et al. Diagnostic performance of bronchoalveolar lavage fluid CD4/CD8 ratio for sarcoidosis: a meta-analysis. EBioMedicine 2016; 8: 302-308.
Dave N, Chevour P, Mahendradas P, et al. Increased aqueous humor CD4+/CD8+ lymphocyte ratio in sarcoid uveitis. Ocul Immunol Inflamm 2018; 1-8. https://doi.org/10.1080/09273948.2017.1421232. [Epub ahead of print].
Kojima K, Maruyama K, Inaba T, et al. The CD4/CD8 ratio in vitreous fluid is of high diagnostic value in sarcoidosis. Ophthalmology 2012; 119: 2386-2392.
Hyldgaard C, Kaae S, Riddervold M, Hoffmann HJ, Hilberg O. Value of s-ACE, BAL lymphocytosis, and CD4+/CD8+ and CD103+ CD4+/CD4+ T-cell ratios in diagnosis of sarcoidosis. Eur Respir J 2012; 39: 1037-1039.
Christophi GP, Caza T, Curtiss C, Gumber D, Massa PT, Landas SK. Gene expression profiles in granuloma tissue reveal novel diagnostic markers in sarcoidosis. Exp Mol Pathol 2014; 96: 393-399.
Broos CE, Koth LL, van Nimwegen M, et al. Increased T-helper 17.1 cells in sarcoidosis mediastinal lymph nodes. Eur Respir J 2018; 51: 1701124.
Gelfand JM, Bradshaw MJ, Stern BJ, et al. Infliximab for the treatment of CNS sarcoidosis: a multi-institutional series. Neurology 2017; 89: 2092-2100.
Cohen Aubart F, Bouvry D, Galanaud D, et al. Long-term outcomes of refractory neurosarcoidosis treated with infliximab. J Neurol 2017; 264: 891-897.
Calvo-Rio V, Santos-Gomez M, Calvo I, et al. Anti-interleukin-6 receptor tocilizumab for severe juvenile idiopathic arthritis-associated uveitis refractory to anti-tumor necrosis factor therapy: a multicenter study of twenty-five patients. Arthritis Rheumatol 2017; 69: 668-675.